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Neuroinflammation and the tissue-resident innate immune cells, the microglia, respond
and contribute to neurodegenerative pathology. Although microglia have been the focus
of work linking neuroinflammation and associated dementias like Alzheimer’s Disease,
the inflammatory milieu of brain is a conglomerate of cross-talk amongst microglia,
systemic immune cells and soluble mediators like cytokines. Age-related changes
in the inflammatory profile at the levels of both the brain and periphery are largely
orchestrated by immune system cells. Strong evidence indicates that both innate and
adaptive immune cells, the latter including T cells and B cells, contribute to chronic
neuroinflammation and thus dementia. Neurodegenerative hallmarks coupled with more
traditional immune system stimuli like infection or injury likely combine to trigger and
maintain persistent microglial and thus brain inflammation. This review summarizes
age-related changes in immune cell function, with special emphasis on lymphocytes
as a source of inflammation, and discusses how such changes may potentiate both
systemic and central nervous system inflammation to culminate in dementia. We recap
the understudied area of AD-associated changes in systemic lymphocytes in greater
detail to provide a unifying perspective of inflammation-fueled dementia, with an eye
toward evidence of two-way communication between the brain parenchyma and blood
immune cells. We focused our review on human subjects studies, adding key data from
animal models as relevant.
Keywords: monocytes, T cells, Treg, Th17, CD4, CD8, neuroimmunology, neuroinflammation
INTRODUCTION
Dementia is a disease of the mind, but the whole body contributes to brain demise. The corollary
is also likely true: the degeneration of the brain likely contributes to the demise of the body.
Chronological age is the proverbial thumb on the scale, weighing down the body and the brain
until their inevitable end.
As an umbrella term, dementia defines a group of disorders associated with the declining
inability to think and remember (cognitive abilities) and negatively affects mood and emotion.
Dementia robs a person of themself and impairs their ability to function independently. Alzheimer’s
Disease (AD) is the most well-known and well-studied type of dementia, but it is only one of
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aging’s many neurodegenerative diseases (Kovacs, 2015, 2020;
Neltner et al., 2016; Nelson et al., 2019; Karanth et al., 2020;
McKee, 2020).
What has become apparent over the last couple of decades
is that a pure AD-type of dementia – that is, one associated
with only amyloid plaques and neurofibrillary tangles – is rare
(Jellinger, 2020). It is true that AD pathological lesions are
common and begin to develop even in middle age (Nelson
et al., 2011). Most people who die over the age of 70 and are
cognitively healthy for their age will have at least some amyloid
plaques or neurofibrillary tangles (Price and Morris, 1999). Most
individuals with profound cognitive decline will have a high
burden of neuropathological changes, including amyloid plaques
and neurofibrillary tangles, vascular, synucleinopathy, and TDP-
43 pathology (Karanth et al., 2020). We also know that the
vascular contribution to cognitive impairment and dementia
(VCID) is profound, and here too, we can see the connection
between the body and the brain (Ighodaro et al., 2017; Blevins
et al., 2020; Zlokovic et al., 2020).
During life, clinical symptoms and biomarkers guide the
physician to classifying a person’s dementia as a vascular-type
or AD-type dementia, for example. Yet, disease confirmation
requires postmortem neuropathological evaluation (Montine
et al., 2012; Abner et al., 2017). This distinction is essential for
our review. Much of the research we will discuss will be probable
AD-type dementia. Few, if any, of the studies will have confirmed
that AD neuropathological changes caused dementia. Moreover,
the understanding of dementia is ever-evolving.
Neuroinflammation is a prominent feature and a likely
contributor to neurodegenerative disease pathogenesis. However,
AD and related dementias differ from autoimmune diseases,
such as multiple sclerosis, in which T and B lymphocytes
invade the central nervous system (CNS) parenchyma. Instead,
in AD and related dementias, the brain-resident macrophages,
microglia, appear to be the primary component of the immune
system acting locally in the CNS tissue (Prinz and Priller, 2017).
In healthy brain, parenchyma, lymphocytes, and blood-derived
monocytes are absent or rare (Prinz and Priller, 2017). In
addition, the CNS barriers establish immune privilege by tightly
regulating the movement of cells and fluid into and out of the
tissue (Engelhardt et al., 2017). Thus, the interaction of the
CNS with the systemic immune system is profoundly different
than other tissues.
While the involvement of blood-derived immune cells in CNS
tissue is limited in AD and related dementias, it is well-known
that a systemic immune response affects the brain. For instance,
an immune response to systemic infection can cause delirium
without immune cells attacking and killing neurons (Perry et al.,
2007). Experimentally, the response to systemic inflammation
causes a behavioral response (i.e., lethargy, anhedonia, decreased
concentration) termed “sickness behavior” (Hart, 1988; Perry
et al., 2007). Multiple direct routes foster communication and
functional impacts of a systemic immune response to the CNS.
For instance, cytokines and other inflammatory mediators in the
blood can enter the brain via the circumventricular organs, or
cross the blood–brain barrier (BBB), leading to increased reactive
microglia (Perry et al., 2007; Erickson et al., 2020).
In addition to microglia, the brain endothelium is a major
cellular target of systemic inflammation. For instance, brain
endothelial cells express high levels of the receptor for one
of the major proinflammatory cytokines, interleukin-1 (IL-1)
(Liu and Quan, 2018; Liu et al., 2019). IL-1 is elevated in AD
patients’ brains (Griffin et al., 1989). The brain endothelial cells
also alter the permeability and transport of substances across
the BBB (Erickson et al., 2020). Systemic inflammation can
alter neurovascular coupling (Iadecola, 2017) and increase the
adhesion of neutrophils to the brain capillaries, blocking blood
flow (Cruz Hernandez et al., 2019). At the extreme, systemic
inflammation also causes hypoxic/ischemic changes, including
small and larger hemorrhagic infarcts (Thakur et al., 2021). Thus,
it is easy to envision how systemic inflammation could synergize
and further exacerbate VCID-related pathology in the elderly.
In older individuals, multiple systemic inflammatory events
often precede and are hypothesized to contribute to downward
spikes in cognitive function (Perry et al., 2007). Thus,
while delirium and sickness behavior are transient, there is
compelling evidence that systemic immune responses and
systemic inflammation have lasting effects on the brain,
particularly in older fragile individuals. Evidence for this
conjecture comes from aged animals given a systemic immune
challenge such as bacterial lipopolysaccharides (LPS) that have
prolonged sickness behavior, increased cognitive impairment,
and increased reactive microglia (Norden et al., 2015).
Individuals with AD also have higher circulating cytokine
amounts compared to healthy controls. For example, across
multiple studies, serum/plasma individuals with AD had more
IL-1β, IL-6, IL-18, and TNFα than cognitively healthy subjects
(Swardfager et al., 2010; Su et al., 2019). Presumably, the
circulating cytokines are elevated from some ill-defined baseline
and are not generated to counter an active infection or injury, but
instead suggest a heightened state of basal inflammation.
Genetics, environment, and systemic diseases such as diabetes
are underlying causes of a “primed” state of inflammation. Aging
is also a significant driver of inflammation. In addition, nearly
every aspect of the immune system is affected by age, collectively
termed immunosenescence (Nikolich-Zugich, 2018). Therefore,
as diseases of aging, AD, and related dementias must also consider
the impact of the aged immune system on the disease.
This review evaluates the evidence for changes in the systemic
immune system with age and dementia. We believe changes in the
immune system may contribute to dementia, particularly when
the immune system responds to disease, infection, or injury. Our
central focus is on the understudied systemic cellular arm of the
immune system. Aging is the inflammatory background common
across dementias; thus, our review starts with an outline of age-
related changes in the systemic immune system. We will then
describe the sparse studies of systemic immune cell differences
in AD that contrast with the extensive understanding of age-
related inflammation. As the number of AD-related studies of
the systemic immune system is limited, we will describe those
studies in greater detail. While animal models are instrumental
in testing mechanisms and therapeutics, we have focused our
review on studies in people, as these studies can provide the most
remarkable insight into the natural history of dementia.
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IMMUNESENESCENCE CHANGES IN
PEOPLE WITH AGE
The progressive decline in immunity contributes to poor
responsiveness to vaccines, increased incidences of infections,
and decreased immunosurveillance of neoplasms amidst a
chronic state of poorly defined inflammation. The decline of
the immune system with age is not limited to one element
due to interplay between the immune cells (both innate and
adaptive), changes to microenvironment (including lymphoid
and non-lymphoid tissues), and alterations in circulating
inflammatory mediators (cytokines and chemokines, among
other soluble factors) (Nikolich-Zugich, 2018). The immune
system’s age-related changes are best described as dysregulated
and not simplistically skewed pro- or anti-inflammatory as
described in many excellent reviews of immunosenescence
in general (High et al., 2012; Nikolich-Zugich, 2018;
Velardi et al., 2020).
Innate Immune Cell Changes With Age
Innate immunity and macrophage/microglia have traditionally
taken center stage in CNS disorders (Bachstetter et al., 2015;
Greenhalgh et al., 2020; Madore et al., 2020; Shahidehpour
et al., 2021). Therefore, we will begin our discussion of
immunosenescence with the innate immune system with a focus
on neutrophils, dendritic cells (DCs), and monocytes.
Neutrophils are the first responder and act locally by migrating
(chemotaxis) to the site of tissue injury or pathogen. Once
the neutrophils leave the circulation by extravasation, they
play essential roles in phagocytosis and killing the invading
microbes. Neutrophils are short-lived in circulation, with a half-
life of 8–12 h that is offset by production of large numbers
(1–2× 1011 neutrophils per day) (Lord et al., 2001). With
advanced age, the number of circulating neutrophils in the
blood is stable, but they proliferate less in response to G-CSF
(Chatta et al., 1993; Born et al., 1995; Wenisch et al., 2000).
Neutrophils in older individuals (66–93 years old) are still
able to increase in number (neutrophilia) in response to a
bacterial infection to reach a normal range (Lord et al., 2001).
The neutrophil’s microbicidal function decreases with age, and
includes reduced chemotaxis, reduced phagocytosis, decreases
in neutrophil extracellular traps, and a slower resolution of
inflammation (Shaw et al., 2010; Montgomery and Shaw, 2015).
To the best of our knowledge, it is not known in people
if neutrophilia, chemotaxis, and extravasation are maintained
in older individuals in response to a brain injury, such as
a cerebral microhemorrhages. In response to lung injury in
mice, neutrophils migrate to the lung similarly in aged and
young adult animals (Nomellini et al., 2008). The neutrophil
response resolved in the young adult animals by 24-h after
the lung injury, but in aged animals, neutrophil numbers
at 24 hrs post-injury were indistinguishable from the 6-
h post-injury peak. Aged neutrophil response was resolved
by blocking CXCR2 dependent chemokine signaling (MIP2
and KC), which did not otherwise adversely affect wound
recovery. These data support the hypothesis that delayed
resolution of the neutrophilic response in the brain of aged
individuals after an injury may exacerbate the secondary damage
caused by the injury.
Monocytes are circulating leukocytes that originate in
the bone marrow from a common myeloid progenitor cell.
Monocytes account for around 5–10% of the circulating
leukocytes in human blood (Guilliams et al., 2018). Monocytes
and monocyte-derived macrophages are from a different
cellular linage than most tissue-resident macrophages (i.e.,
microglia), which have an embryonic origin from yolk sac
progenitors (Prinz et al., 2017). In humans, monocytes
can be classified as classical HLA-DR+CD14+CD16−,
intermediate HLA-DR+CD14+CD16+, and non-classical
HLA-DR+CD14lowCD16+ (Cros et al., 2010; Hearps et al., 2012;
Guilliams et al., 2018; Figure 1). Classical monocytes are about
85% of all monocytes and remain in circulation for around 1 day
as they traffic to tissues, such as the intestine, to repopulate the
tissue-resident macrophages. Alternatively, classical monocytes
can differentiate into non-classical monocytes, which can
live for 7 days in humans. However, non-classical monocytes
might develop without first becoming a classical monocyte
(Guilliams et al., 2018).
The replacement of tissue macrophages by classical monocytes
is not believed to occur in the CNS, at least not in the healthy
brain (Waisman et al., 2015; Herz et al., 2017). However, much of
what we know about the turnover of tissue macrophages is from
rodent studies. There is only limited understanding of microglia
replacement in people by monocyte-derived macrophages and
the influence of aging, injury, and disease on these processes
in people is not well described. The non-classical monocytes
have been found to have important functions in patrolling
the vasculature, including the arterial, capillary, and venous
compartments (Guilliams et al., 2018), and this could be a
mechanism for how monocytes might sense changes to the
cerebral vasculature as part of VCID.
The number of monocytes increases linearly with age and
comparing the number of monocytes in 20- to 30-year-old
individuals to the monocyte numbers in 80- to 90-year-old
people, there is an approximate tripling of monocyte numbers
with age (Della Bella et al., 2007; Alpert et al., 2019). The
relative proportion of non-classical and intermediate monocytes
also increases with age, while classical monocytes decrease or
remain unchanged (Nyugen et al., 2010; Seidler et al., 2010;
Hearps et al., 2012; Figure 1). Without stimulation, a decrease
in TNFα and IL-6 positive monocytes is seen with age (Nyugen
et al., 2010). Upon stimulation of the toll-like receptors (TLRs),
intermediate CD11c+ monocytes from aged individuals produce
less inflammatory cytokines (IL-6 and TNFα) in response to
TLR1/2 ligands, with no difference between young and old
monocytes for TLR2/6 heterodimer (LTA), TLR4 (LPS), TLR5
(flagellin), and TLR7/8 (poly(U)) ligands (van Duin et al.,
2007). Whereas classical monocytes respond similarly between
young and old individuals following TLR4 stimulation, aged
intermediated and non-classical monocytes had a greater increase
in TNFα than the respective young monocyte populations
(Hearps et al., 2012). While the magnitude of the initial response
to TLR stimulation may be unaffected by age, aged murine
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FIGURE 1 | Summary of age-related changes in monocyte and dendritic cells. (A) In the blood of older aged people, there is a decrease in the proportion of classical
monocytes, while the intermediate and non-classical monocyte populations are increasing compared to younger adults. (B) Monocytes also have an age-dependent
decrease in proinflammatory cytokines at baseline, but with TLR4 stimulation (LPS) the aged monocytes produce more proinflammatory cytokines than monocytes
from younger individuals. (C) There are age-related changes in subpopulations for dendritic cells (DC), and (D) the aged DCs produced more proinflammatory and
less anti-inflammatory cytokines.
macrophages have an impaired ability to end inflammatory
responses (Pattabiraman et al., 2017).
Dendritic cells are the major antigen-presenting cells and play
a critical role in bridging innate and adaptive immune responses.
DCs can be divided into plasmacytoid DCs (pDCs), myeloid
DCs (mDCs), and monocyte-derived DCs (MoDCs) (Figure 1C).
Circulating pDC frequencies decrease with age, while the
numbers of circulating mDCs and MoDCs are age-independent
(Agrawal et al., 2017). However, DC phenotypes change with age.
Unstimulated DCs from aged individuals have higher secretion of
proinflammatory cytokines that likely contribute to age-related
inflammation, or inflammaging (Figure 1D). DCs stimulated
with LPS produce higher concentrations of proinflammatory
cytokines and lower concentrations of an important anti-
inflammatory cytokine, IL-10. For an excellent comprehensive
review of DCs changes with age, see Agrawal et al. (2017).
Adaptive Immune Cell Changes With Age
Aging polarizes the immune system in favor of the innate
immune response with a profound decline in adaptive immunity
(Figure 2). The hematopoietic stem cell (HSC) pool declines
with age and is skewed toward the production of myeloid
cells (Dykstra et al., 2011). T cells’ progressive decline with
age continues with lymphopoiesis and the age-related decline
of thymic lymphoid progenitors that in turn reduce T cell
generation (Berent-Maoz et al., 2012). The thymus is stable in
size with age in humans, but the microenvironment is altered
with adipose tissue replacing healthy tissue that supports T cell
development (Velardi et al., 2020). As the output of naïve T cells
from the thymus slows with age, the body switches to a peripheral
proliferation of T cells to maintain the pool of naïve cells in
circulation (den Braber et al., 2012).
Episomal DNA fragments are excised during T-cell receptor
(TCR) gene rearrangement. These episomal DNA fragments,
called TRECs, provide a direct estimate of de novo T cell
generation, as they are not regenerated and are thereby diluted
in dividing peripheral T cell (Kong et al., 1999; Hazenberg
et al., 2000; Ribeiro and Perelson, 2007). By the age of
55 years old, it is estimated that only 5% of naïve T cells
are produced in the thymus (Murray et al., 2003), and overall
thymic output is decreased by more than 95% in 60-year-
old people compared to 25-year-old people as measured by
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FIGURE 2 | Summary of age-related changes in systemic immune function.
(1) As we age, there is an imbalance in the production of innate immune cells
and adaptive immune cells that favor cells of the myeloid lineage. (2) The
microenvironment decreases with age, and there is a reduction in recent
thymic emigrants (RTEs), reducing the naïve T cell poll in the circulation. (3)
Antigen presentation by dendritic cells declines with age. (4) In the blood, the
immunosenescence leads to a state of chronic inflammation, associated with
elevated circulating cytokines, a decrease in naïve T cells able to respond to
new pathogens, and monocytes over-produce inflammatory mediators and
fail to resolve the inflammatory response.
TREC (Naylor et al., 2005). Unlike mice, which produce most
naïve T cells through thymic output, humans rely primarily
(90% in young adults) on peripheral T cell proliferation
(den Braber et al., 2012).
The decline in HSC polarization and thymic function with age
is important following immunological insults such as infection
and cancer when the immune system can be depleted in older
individuals who cannot subsequently recover it (Velardi et al.,
2020). Latent persistent infections are also part of the secondary
changes leading to immunesenescence (Nikolich-Zugich, 2008).
Overall numbers of T cells in circulation are relatively
unaffected by age, despite the decline in recent thymic output.
However, there are changes in the distribution of different T cell
subsets. The naïve T cells in older individuals have increased
turnover, and virtual memory cells’ formation replaces the lost
recent thymic emigrants. The virtual memory cells lose some
of the naïve T properties, secrete Th1-type cytokines, and have
decreased proliferation compared to naïve T cells (Nikolich-
Zugich, 2014). Naïve CD8 T cells also decline, while naïve
CD4 cells are more stable with age (Wertheimer et al., 2014).
While the diversity of CD4 T cells is maintained through
much of adulthood, a rapid decline in diversity was reported
over the age of 70 years (Naylor et al., 2005). For instance,
regulatory T cells (Tregs) and Th17 cells numbers decline
with age (Vukmanovic-Stejic et al., 2011; Schmitt et al., 2013;
Alpert et al., 2019). Moreover, there is a mismatch of cell number
and cell function with age.
Our recent work compared combinatorial cytokine profiles
generated by CD4+ T cells from lean, normoglycemic older
(average age ∼60) and younger (average age ∼32) subjects
and concluded that Th17 cytokines dominate at least part of
the inflammatory landscape in older subjects (Figure 3). The
age-related Th17 profile is reminiscent of a type 2 diabetes-
associated Th17 profile (Ip et al., 2016) and raises the possibility
that age-related overexuberance of Th17s foster age-related
declines in metabolic control. T cells from older compared to
younger subjects had defects in autophagy and mitochondrial
bioenergetics that associate with redox imbalance, and thus
mirror age-related changes in non-immune cell types. The
importance of autophagy defects in age-related inflammation,
or inflammaging, were highlighted in cause/effect studies that
impaired the autophagy machinery in T cells from young subjects
with siRNA. This manipulation disrupted redox balance and
activated Th17 profile cytokines in young cells by activating the
Th17 master regulator STAT3, which in turn bound IL-17A and
F promoters. Surprisingly, mitophagy-targeting siRNA failed to
activate the Th17 profile in CD4+ T cells from young subjects,
consistent with the idea that non-mitochondrial autophagy
plays an independent role in age-related inflammation. Overall,
our data support a model in which age-related changes in
mitochondrial bioenergetics and non-mitochondrial autophagy
converge to promote inflammaging (Bharath et al., 2020). The
relationship between the age-associated CD4+ T cell profile and
cognitive decline with age remain unexplored.
FIGURE 3 | Age-related TH17 changes. Bharath et al. (2020) demonstrated
that peripheral blood CD4+ cells from healthy older adults (∼60 years old) had
an exaggerated TH17 profile. The TH17 signature was driven by impaired
non-mitochondrial autophagy and dysfunctional mitochondria, at least in part
via a STAT3 dependent mechanism.
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SYSTEMIC IMMUNE CHANGES SEEN IN
PEOPLE WITH DEMENTIA
An ever-growing body of evidence shows interaction between
the immune and nervous systems (Galea et al., 2007; Prinz and
Priller, 2017). Studies dating back to the 1980s provided evidence
that both the adaptive and innate immune cells are altered in
people with dementia. This section describes changes in systemic
immune cells highlighted by this work. The interested reader
should also consider previous reviews on the topic (Rezai-Zadeh
et al., 2009; Sommer et al., 2017) and reviews of systemic immune
changes in animal models of neurodegenerative disease (Nevo
et al., 2003; Cao and Zheng, 2018; Mayne et al., 2020).
In the 1980s, studies evaluated both changes in proportions
of different immune cell populations (i.e., immunophenotyping)
and how immune cells differed in response to a stimulus or
mitogen (i.e., immune function). Over the subsequent 40 years,
our understanding of the immune system has dramatically
expanded. For example, we now have further divided T
lymphocytes into smaller, specialized populations of cells using
multi-color flow cytometry with parallel functional studies. Also,
populations of cells such as “suppressor” T cells, which were
dismissed in the late 1980s as artifacts, have now become
identified as Tregs, arguably the most intensively studied CD4+
T cell subset in the last decade. We also know that there are
many forms of dementia in the community, with a pure AD being
relatively rare. So, when going back into the archives of older
research, one must be aware of the limitations but also appreciate
the strengths of these early studies.
Whole Blood Cell Counts in AD and
Related Dementias
One of the primary immunological changes seen with age in
humans is the immune system’s polarization in favor of the innate
immune response with a profound decline in adaptive immunity.
Are further changes seen in the balance between innate and
adaptive immunity in people with dementia? van der Willik et al.
(2019) addressed this question in a powerful but simple way
in the Rotterdam Study – a large prospective population-based
cohort study of older adults (Ikram et al., 2017; van der Willik
et al., 2019). As part of the Rotterdam study, van der Willik
et al. (2019) evaluated blood cell counts in 8313 participants.
Longitudinal evaluation of the complete blood counts was done
for multiple visits (every 3–5 years) during a 13-year period. The
study excluded people with dementia at the start of the study.
Participants were screened for dementia at baseline, and each
visit using the Mini-Mental State Examination (MMSE) and the
Geriatric Mental Schedule score. During the follow-up period,
664 of the cognitively healthy individuals developed dementia,
with 82% being probable AD-type dementia and 5% probable
vascular dementia (VaD).
To evaluate the balance of innate vs. adaptive immunity,
they looked at ratios amongst blood granulocytes, platelets,
and lymphocytes, which has recently been proposed to be
a validated (albeit simple) measure of changes in immunity
(Hu et al., 2014; Templeton et al., 2014a,b; Fest et al., 2018).
Three predictive ratios were evaluated: (1) granulocytes-to-
lymphocytes; (2) platelets-to-lymphocytes, and (3) a total
systemic immune-inflammation index (integrated peripheral
lymphocyte, neutrophil, and platelet indicator). van der Willik
et al. (2019) found that altered balance between innate
(granulocytes) and adaptive immunity (lymphocytes) was
associated with an increased risk for developing all-cause
dementia over those 13 years (median follow-up 8.6 years)
(Figure 4). These results were consistent when correcting only for
age and sex or adjusting the model by adding additional variables
into the model (education, smoking status, body mass index,
diabetes mellitus, history of stroke, and APOE4 carriers). The
immune cell balance changes were informative, suggesting that
dementia was exacerbating the normal age-related changes in the
immune balance – more innate granulocytes and fewer adaptive
immune cells. VaD showed greater hazard ratio changes for
increased innate activity (granulocyte number, and granulocyte-
to-lymphocyte ratio). VaD associated with lower indicators
of adaptive immunity (lymphocyte number, and platelet-to-
lymphocyte ratio) in comparison to all-cause dementia and AD.
These results are in general agreement with four earlier studies
that evaluated blood count changes in people with dementia,
which found a decrease in lymphocyte number and increase
in neutrophil number in the AD vs. the aged-matched control
groups (Tollefson et al., 1989; Kalelioglu et al., 2017), and
increased neutrophil-to-lymphocyte ratios (Kuyumcu et al., 2012;
Rembach et al., 2014; Kalelioglu et al., 2017). In contrast, one
study found no difference in lymphocytes between AD and
FIGURE 4 | Blood cell counts and risk for all cause dementia. van der Willik
et al. (2019) evaluated blood cell counts on 8313 participants who were
dementia-free at the start of the study (mean age: 61 years old at the start).
During a median follow-up of 8.6 years, 664 developed dementia. For those
who did not have a stroke during the study (N = 8008), changes in blood cell
counts, and the ratio of blood cell populations were statistically associated
with dementia risk. Plotted results are from Table 3 of van der Willik et al.
(2019). *p < 0.05.
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control participants (Dysken et al., 1992). Differences in study
design (cross-sectional), smaller sample size, age at the start of
the study, and covariate adjustment should all be considered
when comparing the results from earlier studies that disagree
with van der Willik et al. (2019). Nevertheless, these studies
provide compelling evidence for dementia-specific disruption of
the immune system atop shifts that characterize healthy aging.
T Cell Immune Phenotyping in AD and
Related Dementias
Leffell et al. (1985) were among the earliest studies to complete
immune profiling in people with AD. Their cross-sectional
study found no change in total T cells, CD4, CD8, or the
ratio of CD4:CD8 cells between the people with probable AD-
type dementia and aged-matched controls. In their concluding
paragraph they stated, “we believe that there is little, if any,
cumulative evidence to support an immunological process in
Alzheimer’s disease.” However, this statement needs context,
as they, and many studies that followed, explored if AD was
caused by an autoimmune attack on neurons similar to multiple
sclerosis, or by infectious agents like prions in Creutzfeldt–
Jakob disease.
In the past 25 years, changes in the major T cell populations
have been evaluated across different stages of dementia
progression, spanning from mild cognitive impairment (MCI)
to severe AD (Table 1). Throughout the late 1980s and 1990s, a
handful of studies evaluated the immune system in people with
dementia (Singh et al., 1987; Antonaci et al., 1990; Licastro et al.,
1990; Araga et al., 1991; Ikeda et al., 1991; Pirttila et al., 1992;
Singh, 1994; Hu et al., 1995; Shalit et al., 1995; Trieb et al., 1996;
Lombardi et al., 1999). The majority of studies found no change
at any stage of disease progression for total T cells (CD3), or
CD4 or CD8 T cells. Some of the studies found no statistical
relationship between dementia and immunological functions.
For instance, IL-2 was equally effective at inducing proliferation
of lymphocytes in AD and control participants (Licastro et al.,
1990). While a few studies found no change in CD4, CD8 or
CD4:CD8 ratios (Ikeda et al., 1991; Singh, 1994), others found
changes in these cell populations (Pirttila et al., 1992). The
changes include a decrease in CD8 cells in probable AD dementia
and an increase in CD8 cells in probable VaD both compared
to age-matched controls (Pirttila et al., 1992; Hu et al., 1995;
Shalit et al., 1995). Shalit et al. (1995) found that the severity
of the neurodegenerative disease correlated with the immune
cell changes including an increase in CD4s and a decrease in
CD8s in severe dementia, despite no differences in CD4 or
CD8 numbers in mild dementia, both compared to controls.
Tregs were found to change by dementia status; however, future
studies are needed to replicate these studies using state of the
art markers for human Treg cells. A single recent report found
that TH17 cells were increased in MCI, but by early AD the
increase in TH17 cells was no longer apparent (Oberstein et al.,
2018). It will be necessary to replicate these changes in future
TABLE 1 | Relationship between dementia status and T cell populations.




←→ (Lueg et al.,
2015)
←→ (Lueg et al., 2015) ←→ (Lueg et al., 2015),
↑ (Gate et al., 2020)
←→ (Lueg et al., 2015),
↓ (Gate et al., 2020)
←→ (Le Page et al., 2017),
←→ (Oberstein et al., 2018),







←→ (Lueg et al.,
2015)
←→ (Lueg et al., 2015),
←→ (Bonotis et al., 2008),
←→ (Shalit et al., 1995)
←→ (Shalit et al., 1995),
←→ (Lueg et al., 2015)
←→ (Lueg et al., 2015) ←→ (Le Page et al., 2017),
←→ (Oberstein et al., 2018),












←→ (Pirttila et al.,
1992)
↓ (Bonotis et al., 2008),
←→ (Richartz-Salzburger
et al., 2007), ↑
(Shalit et al., 1995),←→
(Pirttila et al., 1992),←→
(Leffell et al., 1985)
←→ (Bonotis et al., 2008),
←→ (Richartz-Salzburger
et al., 2007),
↓ (Shalit et al., 1995),
↓ (Pirttila et al., 1992),
←→ (Leffell et al., 1985)
←→ (Bonotis et al., 2008),
←→ (Richartz-Salzburger
et al., 2007),
↑ (Shalit et al., 1995),
↑ (Pirttila et al., 1992),
←→ (Leffell et al., 1985)
←→ (Busse et al., 2017),
←→ (Rosenkranz et al., 2007)
Early AD vs. MCI ←→ (Lueg et al.,
2015)
←→ (Lueg et al., 2015) ←→ (Lueg et al., 2015) ←→ (Lueg et al., 2015) ←→ (Le Page et al., 2017),
←→ (Saresella et al., 2010)
Late AD vs. early
AD
↓ (Bonotis et al., 2008) ←→ (Bonotis et al., 2008) ←→ (Bonotis et al., 2008)
AD vs. other
dementia
←→ (Lueg et al.,
2015),
←→ (Busse et al.,
2017)
←→ (Lueg et al., 2015),
←→ (Busse et al., 2017)
←→ (Lueg et al., 2015),
←→ (Busse et al., 2017)
←→ (Lueg et al., 2015) ←→ (Busse et al., 2017),←→
(Rosenkranz et al., 2007)
AD vs. VaD ←→ (Busse et al.,
2017)
←→ (Busse et al., 2017) ←→ (Busse et al., 2017) ←→ (Busse et al., 2017)
The symbols indicate the following:←→ no change, ↑ increase in cell population, and ↓ decrease in cell population. MCI (mild cognitive) impairment (CDR 0.5), Early AD
(CDR 1–2), and Late AD (CDR 3). If the clinical dementia rating (CDR) scale or MMSE was not specifically noted in the paper, the cases were assumed to be LATE AD.
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 June 2021 | Volume 15 | Article 652111
fncel-15-652111 June 16, 2021 Time: 16:8 # 8
Lutshumba et al. Systemic Immunity and AD
FIGURE 5 | Changes in T cell subsets in AD. Recent studies have identified
changes in effector memory and terminally differentiated T cells in AD patients’
peripheral blood compared to aged-matched controls. The changes in the T
cells subsets were found to significantly correlate with cognitive scores.
References for changes correspond to the following: [1] (Busse et al., 2017)
and [2] (Gate et al., 2020). The symbols indicate the following:←→ no
change, ↑ increase in the cell population, ↓ decrease in the cell population in
AD cases compared to aged-matched controls. *p < 0.05.
studies and evaluate these changes in a longitudinal instead of a
cross-sectional study.
Two recent studies have evaluated naïve, central memory
(TCM), effector memory (TEM), and terminally differentiated
(TEMRA) CD4 and CD8 subsets (Busse et al., 2017; Gate et al.,
2020; Figure 5). The four subsets of T cells were identified by
the expression of lymph node homing molecule receptor, CCR7.
Along with the expression pattern of the leukocyte common
antigen (CD45) isoforms RA and RO. During the transition from
naïve to TEM the expression of CCR7 is lost when the TCM are
restimulated by antigen. When the TEM terminally differentiate,
they stop expressing CD45RO and re-express CD45RA. It was
found that the CD8+ TEMRA were increased in the blood
of MCI/AD patients. The percentage of these CD8+ TEMRA
cells were strongly correlated with worse cognitive function
(Gate et al., 2020). In the AD patient’s cerebrospinal fluid,
clonal expansion of the CD8+ TEMRA was found. While the
authors identified TCRβ sequence with known specificity for the
Herpesviridae Epstein–Barr nuclear antigen 3, they cautioned
against suggesting that these finding provided evidence for a link
between Epstein–Barr virus and AD, as it has infected up to 95%
of American adults, and their caution is well founded.
T Cell Immune Function in AD and
Related Dementias
Skias et al. (1985) used immunopanning to enrich for CD4 and
CD8 cells from peripheral blood mononuclear cells (PBMCs)
to evaluate function of the T cells. In the cross-sectional design
they included 16 AD (mean age 75) and 14 age-matched controls
(Skias et al., 1985). They found in the CD8 enriched cell fraction
that upon stimulation with pokeweed mitogen the CD8 cells from
AD participants were less able to suppress IgG production from
B cells. Skias et al. (1985) postulated that the changes in immune
function in AD could be a form of “accelerated aging” and that the
“selective neuronal loss could lead to perturbed neural influences
on the immune system.”
Miller et al. (1981) also found that lymphocytes from AD
participants compared to aged-matched controls (mean age 75.5)
had less response to the mitogen phytohemagglutinin, indicating
an overall blunted immune response. They also reported
increased immune suppression activity in the AD lymphocytes
in response to another non-specific mitogen, concanavalin-A,
compared to lymphocytes from age-matched controls. Miller
et al. (1981) had a third view on the immune changes in AD. They
speculated that AD might be more like a chronic viral infection
in the way that it suppresses immunity. Further, they speculated
that the “active impairment of a particular immune response
has allowed an infectious agent to gain a foot in [dementia
patients], resulting in central nervous system damage.” While
these findings are 40 years old, and could be more compelling,
the ideas proposed are interesting and should be revisited.
Trieb et al. (1996) tested if PBMCs from AD cases would
respond to amyloid precursor protein (APP) fragments (Aβ1–
28). The study included 20 old healthy controls (mean age 71),
20 young healthy controls (mean age 25), and 10 participants
with AD (moderate severity n = 8 and severe n = 2; mean age
73). They found that the AD PMBCs had a decreased response
to Aβ1–28 compared to the young or old controls as measured
by a proliferation assay, with no effect of age. While it could be
speculated that this was some sort of tolerance to Aβ stimulation
in AD cases, the effects could also be from a general lack of
effector function in PMBC from individuals with AD. Subsequent
studies found no difference in the ability of PBMCs to respond to
Aβ1–42 between AD vs. control participants (Giubilei et al., 2003;
Rocha et al., 2012).
Singh (1994) stimulated PBMCs from probable AD cases
or controls with LPS, which activates mainly innate immune
cells through TLR4. They found that not only was there a
bias toward increased innate immune cell numbers, but those
innate immune cells produced 2.3-fold more IL-1 and threefold
more IL-6 compared to age-matched control PBMCs (Singh,
1994). Lombardi et al. (1999) expanded upon these findings
by measuring a more comprehensive panel of cytokines and
including VaD and Parkinson’s disease groups. They found that
LPS stimulated whole blood cultures from AD patients showed
differences in cytokine production compared to results from
aged-match controls and the VaD and Parkinson’s disease groups
(Figure 6; Lombardi et al., 1999). The results support the case
for an exaggerated innate immune response and also suggest
signatures of immune function that are unique to different
forms of dementia.
By the age of 40, individuals with Down’s syndrome will
have AD-neuropathological changes in their brains, and the
majority will develop dementia. Park et al. (2000) isolated
peripheral blood monocytes from individuals (range 26–68 years
old, mean 45 years old) with Down syndrome and age-matched
controls and stimulated the cells with LPS. They found no
difference in TNFα, IL-6, or IL-8. In contrast to Singh (1994)
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FIGURE 6 | Whole blood cultures show an exaggerated response to LPS.
(A) Lombardi et al. (1999) stimulated whole blood cultures from individuals
with Alzheimer’s disease (AD), vascular dementia (VaD), and compared these
to aged-matched controls. Cell culture supernatant was collected at 24-h
intervals for 72 h for ELISA cytokine assays. (B) All cytokines measured
showed higher cytokine production in the AD group, compared to the control
or VaD groups. The plotted data is from the 24 h post-stimulation time point,
from Table 3 of Lombardi et al. (1999). A similar trend was seen for the 48 and
72 h post-stimulation timepoint. *p < 0.05 compared to control.
and Lombardi et al. (1999), they found that monocytes from
Down’s syndrome individuals produced 30% less IL-1β than the
aged match controls.
Stimulating PBMCs from AD patients or aged-matched
controls with either PHA or anti-CD3/CD28 it was found that the
AD patients had an increased proinflammatory IL-1β response,
presumably from the innate immune cells, a decreased in the
anti-inflammatory cytokine IL-4, presumably from T cells (Reale
et al., 2004; Rocha et al., 2012). Stimulating the PBMCs with
PHA-M, a T cell activator, IL-2 was increased in the late AD,
but not in the early AD compared to control (Shalit et al., 1995).
AD patient CD8 T cells stimulated with PMA and ionomycin
produced more IFNγ and TNFα than CD8 T cells from age-
matched controls (Gate et al., 2020). In summary, both innate and
adaptive immune cells’ products upon activation are dysregulated
in people with dementia. More work is needed to understand
the inflammatory signature of this dysregulation and the role of
immune cell cross-talk, as these areas will be important targets for
therapeutic intervention.
B Cell Changes in AD and Related
Dementias
Despite the emerging understanding of roles for T cells in
AD and related dementias, few studies explored roles for
B cells in AD, although B cells coordinate with T cells to
define functions of the adaptive immune system. B cells can
proliferate in T cell-dependent manner or independent manner
with the latter producing immunoglobulins (Ig), also termed
antibodies, with low affinity and failure of memory B cell
development (Defrance et al., 2011). B cell proliferation in a
T cell-dependent manner is facilitated by helper T cells after
antigen-presentation to give rise to memory. In addition to
producing Ig, B cells act as antigen presenting cells to induce T
cell activation through co-stimulation and cytokine production
(Chalasani and Rothstein, 2014).
Age-related diseases like chronic lymphocytic leukemia and
autoimmune diseases show extremes of B cells changes with age
(Candore et al., 1997; Chiorazzi and Ferrarini, 2003). While there
is a decrease in total B cells in the elderly, age-related increases
in particular B cell populations may be involved in increased
inflammation (Colonna-Romano et al., 2009; Bulati et al., 2014).
Unfortunately, only a few reports describe B cell status in AD
and related dementias. IgG+IgD−CD27− B cells are increased
in peripheral blood of patients with moderate to severe AD,
compared patients with mild AD or no cognitive impairment
(Bulati et al., 2015). B1 cells, which make IgM and are considered
more “innate-like” in function, have been implicated in amyloid-
beta clearance in people (Agrawal et al., 2018) and mice (Baulch
et al., 2020): both B1 and IgM are decreased in an AD-relevant
mouse model (Baulch et al., 2020). Using an in vitro model with
B cells from AD patients further suggests a role for B cells in
amyloid-beta plaque formation (Dezfulian, 2018). Despite the
paucity of studies, the available evidence supports the future
exploration of B cell function in AD and related dementias.
CONCLUSION AND FUTURE
DIRECTIONS
Aging causes a functional decline and reorganization of
the immune system collectively termed immunesenescence,
which leads to a chronic state of inflammation that damages
many organs, including possibly the brain. Chronic systemic
inflammation is greater in people with AD (Holmes et al., 2009).
Immunesenescence leaves the body vulnerable to infections
and suboptimal vaccine responses through poorly understood
mechanisms and leaves the immune system at the risk of being
depleted following an infection or injury. In people with AD
dementia, and perhaps other dementias, the age-related change
in immune system cell distribution and function is exacerbated.
The balance of innate vs. adaptive immune systems is further
skewed toward innate immune function in people with AD (van
der Willik et al., 2019). The decrease in memory T cells and
increase in clonal expansion of TEMRA T cells tracks closely with
decline in cognitive function in AD (Gate et al., 2020). When
the systemic immune cells encounter stimuli they are primed
toward an exaggerated proinflammatory response (Singh, 1994;
Godbout et al., 2008).
In the neuro-centric view, AD starts in the brain. This could
be, as proposed by Leffell et al. (1985), that AD is caused either
by a neuron-targeted autoimmune attack or by an infection
in the brain that damages the neurons, and that the immune
system is altered in response to this infection. Many infectious
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agents have been proposed over the years (Readhead et al., 2018;
Drayman et al., 2019; Abbott, 2020; Allnutt et al., 2020; Gate
et al., 2020; Rizzo, 2020). The alternative neuro-centric view is
that as neurons are degenerating, there is a loss of neural trophic
support, which suppresses the immune system, as postulated by
Skias et al. (1985). However, while both of these views have
merit, we believe that the current evidence does not support these
interpretations.
From the immunological centric standpoint,
immunosenescence comes first. As the immune system becomes
dysfunctional, we speculate that it is no longer able to protect
the brain. The genetic evidence strongly supports the role of
the immune system in AD (Kunkle et al., 2019; Andrews et al.,
2020; Neuner et al., 2020), as many genetic risk variants associate
with innate immunity. Could these genetic risk variants further
drive the age-related imbalance in adaptive vs. innate immunity?
Or are genetics additive to the effects of aging – that is, more
innate cells that are more proinflammatory? Currently, the vast
majority of work on innate immune cells in AD is focused on the
microglia. Comparatively, much less is known about how AD
risk genes affect the systemic innate immune function, and more
work is needed in this area.
While it is often assumed that the decline in dementia is steady
and progressive, at the individual level, the decline is more zigzag
with troughs of decline, which are speculated to correspond to life
events (infections, diseases, surgeries, etc.) (Perry et al., 2007). If
a dysfunctional immune system leads to more numerous/serious
infections, or exaggerated responses to the infection, could
these events be driving a neurodegenerative decline? One could
speculate that it is not until that immune system is challenged
(for example, by a urinary tract infection) that an exaggerated
immune response damages the brain. However, more work is
needed to test these possibilities.
In conclusion, there is compelling correlational evidence
that the systemic immune system is disrupted in people
with dementia. There is also strong evidence that genetic
polymorphisms in immune function, including HLA and
TREM2, modify the risk for developing AD. Still, there are
several essential questions. Our review provides compelling
evidence that the immune system is altered in AD, but our
current knowledge of how the immune system is changed is
fragmented. Future studies (Figure 7) are needed to provide
a complete picture of how the immune system changes in
people with healthy cognitive aging and those who transition
FIGURE 7 | Systems approach to evaluate systemic immune changes in dementia. In a community-based cohort of individuals who are followed longitudinally and
have agreed to brain autopsy and donation, the study can begin with a cross-sectional design of participants without cognitive impairment and comparing those
with mild cognitive impairment to profound dementia, and incorporating clinical evaluations as part of the study (1). By piggybacking on a larger study that
incorporates genomic (2), blood collection (3), and fluid biomarker assessment (including assays for systemic inflammation), (4) it is possible to leverage ongoing
cohort studies to better define the role of immune dysfunction in AD. Peripheral blood mononuclear cells (PBMC) are isolated from the fresh whole blood and are
archived for future studies (3). The isolated PMBCs can be used for gene expression and gene sequencing to identify changes in immune cell populations and clonal
expansion of T cells (5). Immunophenotyping of immune cell subsets can be done to evaluate changes in a population of immune cells (6). Select populations of
immune cells can be enriched (7). The PBMC or select cells can be directly stimulated with activators such as LPS or CD3/CD28 (8), to evaluate cellular mechanisms
and therapeutic targets, inhibitors can be added along with the mitogens (9). The cell culture supernatant can then be used for cytokines multiplex immune profiling
assays (10). By enriching the cross-sectional design for healthy controls, it is possible to evaluate people’s possible conversion into varying neurodegenerative
diseases (11), which are ultimately pathologically confirmed at autopsy (12). The wealth of data that is captured will require a very robust statistical and
bioinformatical infrastructure to integrate all the data (13). Finally, “hits” will require validation in a subsequent set of study participants, and clinical experimentation
can test positive intervention strategies targeted at restoring the immune balance (14).
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into neurodegenerative disease. Such studies are costly, but
by partnering and incorporating immunological evaluations
as part of ongoing analysis of cognitive state in community
cohorts (Schmitt et al., 2012), we can address many unresolved
questions in the field.
In addition to understanding the natural history of immune
changes associated with AD and related dementias, it will
also be important to establish causation, mechanisms of
dysfunction, and ultimately therapies. Future studies will require
a translational approach using animal models. Example studies
from animal models show the influential role of the adaptive
immune system as a modifier of brain function. For example,
dietary and metabolic manipulations have been shown to lead
to an increase in Th17s and Th17-cytokines (IL-17, IL-22) that
cause cognitive dysfunction in the absence of amyloid plaques
and neurofibrillary tangles (Faraco et al., 2018). Alternatively,
boosting adaptive immune system function through blockade
of immune checkpoints, such as PD-1, improved outcomes in
multiple AD-relevant animal models (Baruch et al., 2015, 2016;
Rosenzweig et al., 2019). In contrast, in Rag2, Il2rγ, double-
knockout mice that lack T cells, B cells, and natural killer cells,
the lack of an adaptive immune system worsens pathology and
neuroinflammation in an AD-relevant mouse model (Marsh
et al., 2016). These animal studies and others suggest that
the adaptive immune system contributes to cognitive decline
(Spani et al., 2015; Jevtic et al., 2017; Unger et al., 2020).
This interpretation is therapeutically promising as it provides
opportunities for manipulation, including approaches such as
IL-7 to replenish the depleted immune system and checkpoint
inhibitors like PD-1. Much more work is still needed. By gaining
a better understanding of the connection between the immune
system and the brain there is great promise in obtaining a more
holistic perspective of how the demise of mind and body both
contribute to dementing diseases.
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